Analyst John Young CFA from Canaccord Genuity maintained a Buy rating on AngioDynamics (ANGO – Research Report) and keeping the price target at $15.00.
John Young CFA has given his Buy rating due to a combination of factors that highlight AngioDynamics’ growth potential and market position. The company is strategically positioned in high-growth markets, such as venous thromboembolism (VTE), focal prostate therapy, and interventional oncology, which are expected to drive significant revenue growth. Particularly, the VTE segment is poised for expansion with the AlphaVac product gaining market share and offering unique procedural advantages over competitors.
Additionally, AngioDynamics’ financial health is solid, with a clean balance sheet, no debt, and a positive cash flow outlook. The stock is currently undervalued, trading at a low EV/Sales multiple, which presents an attractive investment opportunity given the company’s growth trajectory and management’s consistent performance in meeting expectations. These factors collectively underpin John Young’s Buy rating for AngioDynamics.
In another report released on April 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $16.00 price target.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ANGO in relation to earlier this year.